ARL3

Across TCGA pan-cancer cohorts, ARL3 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ARL3 data layer compared with 26 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ARL3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARL3 expression acts as an unfavorable survival marker.

OV, COAD, and UCEC are the cancer types where ARL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.488	0.900	.015	24	view →
COAD	DFS	Median	III,IV	0.890	1.000	.030	12	view →
UCEC	OS	Quartile	II,III,IV	0.510	1.000	.037	8	view →
HNSC	OS	Quartile	All	0.603	0.862	.011	7	view →
CCRCC	OS	Quartile	II,III,IV	0.690	1.000	.016	6	view →
LUAD	OS	Quartile	II,III,IV	0.748	1.000	.032	4	view →
PDAC	DFS	Median	III,IV	0.426	0.835	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ARL3–OV (DFS)

Open the OV breakdown →